---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-027798"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-08-27T23:59:59+00:00"
generated_at: "2026-05-17T09:44:07.739864+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports positive Annamycin AML trial: median OS 15 mos for CR, 12 mos for 2L

## Summary
- Phase 1b/2 MB-106 trial completed; median OS 15 months for complete remissions (n=8), 12 months for 2L efficacy evaluable (n=9).
- Median OS for ITT population (1L-7L) was 9 months, exceeding typical 4-6 months for relapsed AML.
- CR rate 36% ITT, 50% in 2L; 50% of CR subjects proceeded to bone marrow transplant; no cardiotoxicity.
- Database lock expected Sep 2025; final clinical study report in Q1 2026; Phase 3 MIRACLE trial enrolling first 45 pts.
- Authorized common shares increased from 100M to 500M effective Aug 21, 2025.

## SEC filing metadata
- accession: 0001437749-25-027798
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-08-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925027798/0001437749-25-027798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925027798/mbrx20250826_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-027798
- JSON: https://secwatch.observer/filing/0001437749-25-027798.json
- Plain text: https://secwatch.observer/filing/0001437749-25-027798.txt

## Key facts
- Governance Changes
  Moleculin Biotech, Inc.: Stockholders approved a Certificate of Amendment to increase authorized common stock from 100,000,000 to 500,000,000 shares, effective upon filing with the Delaware Secretary of State on August 21, 2025 (effective 2025-08-21).
  - Change: charter amendment
  - Effective: 2025-08-21
  source text: As previously disclosed, at the Moleculin Biotech, Inc. (the “Company”) annual meeting of stockholders held on August 18, 2025, the Company’s stockholders approved, among other matters, a proposal to approve a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate Amendment”) which would amend the Company’s existing certificate of incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 100,000,000 shares to 500,000,000 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774925027798/0001437749-25-027798-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.